---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/42235791.md"
description: "$Regencell Bioscience(RGC.US) fell -12%, behind which is an ongoing securities class action lawsuit—the deadline for lead plaintiff claims from investors just passed, and the market is starting to take seriously the company's foundation of zero revenue and continuous net losses. The previous wave of impulsive gains lacked earnings support from the start, relying on narrative and liquidity; once the lawsuit enters the process, the valuation pressure on small caps is persistent, not a negative that can be digested in a single day."
datetime: "2026-06-26T10:10:15.000Z"
locales:
  - [en](https://longbridge.com/en/topics/42235791.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/42235791.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/42235791.md)
author: "[本职喵星人](https://longbridge.com/en/profiles/27713076.md)"
---

# $Regencell Bioscience(RGC.US) fell -12%, behind wh…


### Related Stocks

- [RGC.US](https://longbridge.com/en/quote/RGC.US.md)